Michael Stebbins, Ph.D. is a geneticist and public-policy expert who served as the Assistant Director for Biotechnology in the Obama White House Office of Science and Technology Policy. He is currently the President of Science Advisors, a science and health consulting firm he founded in 2018 to provide science, technology, and public policy guidance to private companies, philanthropies, and non-profit organizations. He is also a Senior Fellow at the Federation of American Scientists. While at the White House, Dr. Stebbins’ work led to large initiatives across the federal government to address antibiotic resistance, protect pollinators, improve veterans’ mental health, increase access to federally funded scientific research publications and data, promote preferential purchasing of antibiotic-free meats, reform the regulatory system for biotechnology products, drive federal purchasing of bio-based products, and improve management of scientific collections. Dr. Stebbins previously served as the Vice President of Science and Technology for the Laura and John Arnold Foundation, science advisor to the Obama Presidential Campaign, and on the Obama White House Transition Team. He is the former director of biology policy for the Federation of American Scientists and worked for U.S. Senator Harry Reid and at the National Human Genome Research Institute. Before coming to Washington, he was a senior editor at Nature Genetics. Dr. Stebbins is on the Board of the Value in Cancer Care Consortium and chair of the Board for Vivli. He serves on the scientific advisory boards for Datavant and Amida Technology Solutions.
The 61 million adults in the United States living with a disability deserve to engage with the world on their own terms.
Publication of detailed scientific methodologies can save researchers time and money, and can accelerate the pace of research.
Comprehensive and reliable mortality data will enable more effective response to rapidly evolving public health challenges.
下一个政府应通过基于证据的方法来优化药物给药和改善预后。
Address pharmaceutical market failures by launching a new program that takes an open-source approach to pharmaceutical R&D.
Require federally funded scientists to share their data. Build an international research data commons. Accelerate scientific progress.
The federal government can directly address the massive market failures at the center of our healthcare enterprise by establishing a new Health Advanced Research Projects Agency.
The principle is simple. The products, information and techniques of some life sciences research could be misused for nefarious purposes, such as bioterrorism, and the scientific community should do everything it can to prevent such misuse without impeding research progress. What is unclear is what steps scientists should take when they have concerns about such […]
To begin the day the NBSB listened to presentations from each of the members of the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE). The Enterprise is coordinated within HHS by the Assistant Secretary for Preparedness and Response and includes the NIH, CDC, FDA and BARDA. PHEMCE’s role in HHS is to coordinate the research, development, […]
The National Research Council (NRC) just released a report that finds that “a National Institutes of Health draft assessment of the risks associated with a proposed biocontainment laboratory at Boston University is “not sound and credible.”” The NRC report came in response to a request by the Commonwealth of Massachusetts for technical input into the […]
动物健康研究所已经确认在伦敦郊外的萨里山口测试了积极的测试。我能找到的最新报告表明,他们下令在暴发地区屠杀300只动物,所有牛的运动和出口都已停止。[…]的网站
嘿,我们找到了伊拉克WMD。他们被存储在联合国!我敢肯定,今晚的新闻将是全新的,但是令人惊讶的是,新闻界的速度越快,这实际上是一种愚蠢行为,而且肯定不是一个很大的公共危险。当然,一个人不能[…]